Background
==========

The concomitant rise in obesity and type 2 diabetes has mustered a global effort to understand the links between nutrient overload and insulin resistance to enable new therapies. The skeletal muscle plays an important role in maintaining systemic glycemic control by mediating a majority of insulin stimulated glucose disposal. Skeletal muscle has been demonstrated to be a primary tissue driving insulin resistance and is the target for several anti-diabetic drugs \[[@B1]-[@B3]\]. Excess lipid accumulation outside of adipose tissue is thought to contribute to diabetes by engaging pathways that inhibit insulin signaling. The mechanisms that lead to the development of lipid-induced insulin resistance remain elusive, but consistent themes converge at pathways implicating inflammation, ER stress, and mitochondrial insufficiency \[[@B4]-[@B7]\].

Skeletal muscle with its high capacity for fatty acid oxidation has been a target for genetic and pharmacological studies intended to restore lipid balance by promoting lipid oxidative pathways. From these studies, multiple mechanisms have been proposed to connect lipid metabolism and defects in insulin sensitivity. For example, mitochondria are the major site for fatty acid oxidation and defects in this process may contribute to lipotoxic pathways. The lipotoxicity hypothesis suggests that accumulation of lipid signaling intermediates interact and disrupt insulin signaling to mediate or exacerbate insulin resistance \[[@B8]-[@B12]\]. The finding that the muscles of patients with type 2 diabetes contained fewer and smaller mitochondria than those of age matched insulin sensitive controls, further supported the concept that mitochondrial deficiency or dysfunction is a driver of insulin resistance \[[@B13]-[@B19]\]. The muscle's decreased mitochondrial content limits its capacity to oxidize fatty acids, resulting in the accumulation of undesirable intramuscular lipids, such as ceramide and DAG \[[@B20],[@B21]\]. Therefore, methods that increase fatty acid oxidation, akin to exercise, in the muscle to relieve the toxicity caused by these lipid intermediates have been sought to improve insulin resistance.

Malonyl-CoA is the substrate for *de novo* fatty acid synthesis and its concentration is dependent on the nutritional status of the cell. Malonyl-CoA is produced by acetyl-CoA carboxylase (ACC) and catabolized by malonyl-CoA decarboxylase (MLYCD, commonly referred to as MCD) in the cytoplasm \[[@B22]\]. Although malonyl-CoA is the substrate for fatty acid synthase (FAS) for the production of fatty acids *de novo*, FAS is not expressed at high levels in skeletal muscle \[[@B23],[@B24]\]. In the skeletal muscle, the primary role of MCD is to decarboxylate malonyl-CoA thereby enhancing fatty acid oxidation by alleviating the allosteric inhibition of malonyl-CoA on the rate-setting step in mitochondrial long chain fatty acid beta-oxidation, Carnitine Palmitoyltransferase 1 (CPT1). Genetic and pharmacological studies to inhibit or activate genes involved in fatty acid synthesis (ACC2) or oxidation (CPT1, MCD, AMPK) have produced conflicting results supporting the benefits of skeletal muscle mitochondrial fatty acid oxidation in models of diet induced insulin resistance \[[@B5],[@B25]-[@B31]\]. Whole body deletion of ACC2, used to promote fat oxidation by decreasing malonyl-CoA levels, produced lean hyperphagic mice that exhibited increased fatty acid oxidation, increased energy expenditure, and improved insulin sensitivity \[[@B32]\]. The potential benefits from decreased malonyl-CoA levels to promote fatty acid oxidation to reduce body mass and increase insulin sensitivity prompted the development of other models of ACC2 deletion. New models of whole body and skeletal muscle ACC2 deletion or pharmacological inhibition of ACC2, exhibited no protection from obesity and insulin resistance, while energy expenditure remained unaffected \[[@B25],[@B26]\].

MCD, an enzyme that promotes fatty acid oxidation, has been used to elucidate the relationship between glucose and lipid oxidation in the development of insulin resistance. Over-expression of MCD in the liver of rats fed a high fat diet was shown to increase fatty acid oxidation and improve whole body insulin resistance \[[@B31]\]. Conversely, the loss of whole body MCD resulted in resistance to diet-induced glucose intolerance, despite high intramuscular levels of triacylglycerol and long chain fatty acids \[[@B33]\]. A study using human cultured skeletal myotubes investigated the effects of shifting substrate oxidation from lipid to glucose via RNA interference-mediated gene silencing of MCD under basal and insulin-stimulated conditions \[[@B28]\]. Reducing MCD expression in human myotubes, led to decreased lipid oxidation of palmitate with a rise in glucose oxidation under insulin stimulation. However, several of these studies are confounded by the loss of both cytosolic and mitochondrial MCD, which is implicated in the clearance of mitochondrial malonate, a cytotoxic metabolite that inhibits succinate dehydrogenase \[[@B34]-[@B39]\].

The interconnective nature of metabolic pathways, coupled with the redundancy and compensatory effects often seen by over-expression and knockout studies make it difficult to tease out the contributions of individual pathways to the pathophysiology of insulin resistance in skeletal muscle. Chemical-genetic techniques have been developed to acutely alter metabolic pathways in a manner that is temporal, cell-specific, and reversible \[[@B40]-[@B42]\]. We have previously shown the posttranslational regulation of MCD in transgenic mice in a tissue specific manner via a biologically inert small molecule, Sheild-1 \[[@B40]\]. The benefits of this methodology over previous models are the ability to control for off target effects of the chemical in nontransgenic controls and the ability to alter metabolic pathways in already pathogenic animal models. Here, we acutely induced MCD in the skeletal muscle of obese and glucose intolerant mice to determine the impact of modulating skeletal muscle fatty acid oxidation in a model of diet-induced obesity. Surprisingly, a two week induction of MCD in skeletal muscle did not alter body weight or ameliorate glucose intolerance, conversely it further impaired insulin signaling in the skeletal muscle of diet-induced obese mice. Furthermore, an acute induction of MCD led to a suppression of fatty acid oxidative genes suggesting a redundant and metabolite driven regulation of gene expression.

Methods
=======

Antibodies and chemicals
------------------------

Rabbit polyclonal antibodies that recognize phospho-AKT (Ser473), Pan AKT, phospho-GSK3b (Ser9), Pan GSK3b, phospho-glycogen synthase (Ser 641), Pan glycogen synthase, phospho-IRS-1 (Ser 302), Pan IRS-1, phospho AMPK (Thr172), AMPKα, were obtained from Cell Signaling Technology. Rabbit polyclonal antibody detecting endogenous MCD was obtained from Abcam and antibodies against HADHA and MCAD were from Genetex. A polyclonal antibody for dsRED that reacts with mCherry was obtained from Clontech. Stabilization of Shield-1 was confirmed with a rabbit polyclonal antibody for FKBP-12 (Thermo Scientific). MitoProfile total OXPHOS Rodent WB Antibody cocktail was obtain from MitoSciences. Alpha-Tubulin protein loading control was obtained from Sigma. Gastrocnemius muscle for tissue analysis of signaling proteins, detection of endogenous recombination markers, and stabilization by Shield-1 was harvested and immediately flash frozen in liquid nitrogen. Total protein was extracted by tissue homogenization in cold lysis buffer consisting of 50 mM Tris-HCl, 150 nM NaCl, 1 mM EDTA, 1% Triton X-100, with protease and PhosStop phosphatase inhibitor cocktail (Roche). Tissue homogenates were pelleted at 16,000 *g* for 30 minutes at 4°C and supernatants collected into fresh, cold microcentrifuge tubes. Protein estimation by Pierce BCA Protein Assay Kit was used to determine protein concentration in supernatants. Proteins were separated using NuPAGE Novex 4-12% Bis-Tris Gels in NuPAGE MOPS SDS running buffer or Bio Rad Mini Protean TGX precast gels. Proteins were transferred to PVDF membranes (0.45 μm), blocked in 5% non-fat milk and detected by immunoblotting with the antibodies above. HRP-conjugated secondary antibodies were detected using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) and detected using the FluorChem Western Blot imaging system (Cell Biosciences). Shield-1 was synthesized as previously reported \[[@B41],[@B43]\]. Shield-1 was dried under a stream of nitrogen gas and reconstituted in 50% *N,N*-dimethyacetamide and 50% of a 9:1 PEG-400:Tween-80 mixture \[[@B42]\]. Shield-1 was administered intraperitoneally.

Animal studies
--------------

Animals were housed in a specific pathogen free barrier facility. Tg-fMCD mice were bred to mice expressing Cre from a muscle specific (human alpha-skeletal actin) promoter obtained from Jackson Laboratory to generate Tg-fMCD^skel^ mice \[[@B44]\]. Tg-fMCD^skel^ and control littermates (WT and Cre transgenic) were maintained on a standard chow diet, with free access to food and water and maintained on a 12 hour light-dark photocycle in a temperature controlled environment. At 7 weeks of age, Tg-fMCD^skel^ and control littermate male mice were transitioned from a standard chow diet to a 60% kcal from fat high fat diet (HFD) (D12492, Research Diets, Inc.) or 10% kcal from fat low fat diet (LFD) (D12450J, Research Diets, Inc.). Body weights were measured weekly. Onset of glucose intolerance was assessed by glucose and insulin tolerance tests. At 19 weeks of age, Tg-fMCD^skel^ and control mice were injected i.p. with 60 mg/kg Shield-1 (40 μl formulated in 50% N,N-dimethylacteamide and 50% of a 9:1 PEG-400:Tween-80 mixture) or vehicle alone. Mice received Shield-1 or vehicle injections every 48 hours for 2 weeks. Glucose tolerance tests were repeated on mice to measure efficacy of Shield-1 treatment to lower fasting blood glucose and increase insulin sensitivity. Mice used for the insulin stimulation studies, were i.p. injected with 60 mg/kg Shield-1 or vehicle every 24 hours for 5 days before the stimulation. Acute insulin stimulation was performed on mice following a 6 hour fast during the light cycle. Mice were injected i.p. with 1U/kg insulin (Sigma, bovine pancreas). Tissues were collected 10 minutes after insulin injection, frozen in liquid nitrogen, and stored at -80°C. Animal experiments were done in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under the approval of the Johns Hopkins Medical School Animal Care and Use Committee.

Glucose and insulin tolerance testing
-------------------------------------

Mice were fasted for 6 hours before i.p. injection with 1.25 mg/g glucose or 0.8 U/kg of insulin (Sigma, bovine pancreas) in a 0.9% NaCl solution. Blood glucose was assayed from tail blood at times, 0, 15 min, 30 min, 60 min, 120 min for the GTT after glucose injection. Blood glucose was assayed from tail blood at times, 0, 15 min, 30 min, 60 min after the insulin injection for the ITT. Serum insulin was collected at the 15 minute time point during the GTT and measured using a mouse insulin ELcISA kit (Millipore).

Malonyl-CoA decarboxylase assay
-------------------------------

Isolated gastrocnemius muscles were assayed for MCD activity following drug and diet treatments via a fluorometric assay as previously described \[[@B40],[@B45]\].

Quantitative real time PCR analysis
-----------------------------------

Isolated gastrocnemius muscles from Tg-fMCD^skel^ and control male mice were frozen in liquid nitrogen and stored at -80°C until homogenization with Trizol (Life Technologies) to isolate RNA. The conversion of RNA to cDNA, was performed by using a high capacity cDNA reverse transcription kit (Applied Biosystems). The following PCR primer pairs were used for this study:

*CPT1B* forward, 5′- GGTCCCATAAGAAACAAGACCTCC-3′, *CPTIB* reverse, 5′- CAGAAAGTACCTCAGCCAGGAAAG-3′, *MCAD forward,* 5′-GTTGAACTCGCTAGGCTCAGTTAC-3′, *MCAD reverse,* 5′-CTCTGTGTTGAATCCATAGCCTCC-3′, *PPAR alpha forward, 5′*-ACAAGGCCTCAGGGTACCA-*3′, PPAR alpha reverse, 5′-*GCCGAAAGAAGCCCTTACAG-*3′, PGC1alpha forward, 5′*-CAGCCTCTTTGCCCAGATCT-*3′,* PGC1alpha reverse, 5′-CCGCTAGCAAGTTTGCCTCA-3′, ACOT1 forward, 5′-GACAAGAAGAGCTTCATTCCCGTG-3′, ACOT1 reverse, 5′-CATCAGCATAGAACTCGCTCTTCC-3, 18S rRNA forward, 5′-GCAATTATTCCCCATGAACG-3′, 18 s rRNA reverse, 5′-GGCCTCACTAAACCATCCAA -3.

Statistics
----------

Statistical analyses were performed using one-way or two-way ANOVA as indicated in the figure legends. Significance is defined when p \< 0.05. Data is represented as mean ± SEM.

Results
=======

In Vivo chemical-genetic regulation of Malonyl-CoA decarboxylase in skeletal muscle
-----------------------------------------------------------------------------------

Lipids mediate insulin resistance in skeletal muscle via an ill-defined mechanism; however, promoting the rate of fatty acid oxidation in skeletal muscle has been proposed to affect insulin sensitivity in this tissue \[[@B30],[@B32],[@B46]-[@B50]\]. Given the importance of MCD in regulating skeletal muscle fatty acid oxidation, we generated transgenic mice where MCD (Tg-fMCD) can be regulated in a cell and chemical specific manner in order to determine the effect of acutely altering fatty acid metabolism in insulin resistance \[[@B40]\]. A cytoplasmic targeted MCD fused to a destabilization domain was cloned downstream of a lox mCherry stop cassette. Therefore, the expression of the transgene is controlled in a Cre-recombinase dependent manner. The destabilization domain was derivatized from FKBP12 (FK506 binding protein 12) enabling reversible and dose dependent protein stabilization with its synthetic ligand, Shield-1 (fMCD) \[[@B41]\]. In order to target the transgene to skeletal muscle, Tg-fMCD mice were bred to mice expressing Cre recombinase from the human alpha skeletal muscle actin promoter, ACTA1, producing Tg-fMCD^Skel^ mice. Thus, we generated mice expressing cytoplasmic MCD that is stabilized by Shield-1 in a skeletal muscle specific manner (Figure  [1](#F1){ref-type="fig"}A).

![**Tissue specific chemically inducible Malonyl-CoA Decarboxylase. (A)** Schematic diagram of the dually regulated MCD transgene. **(B)** Tg-fMCD^skel^ mice were injected i.p. with vehicle or Shield-1 at various doses. Samples were collected 24 hours after injection and gastrocnemius muscle samples were probed for the indicated proteins. **(C)** Dose and delivery vehicle analysis of Shield-1 in Tg-fMCD^skel^ mice. Gastrocnemius muscles from mice injected i.p. with vehicle or Shield-1 at varying doses and delivery methods were collected 24 hours post treatment to determine efficacy of Shield-1 stabilization by western blot for FKBP12.](1471-2091-15-20-1){#F1}

In order to determine the appropriate dose to achieve effective transgene stabilization we injected Tg-fMCD^Skel^ mice with increasing concentrations of Shield-1 in corn oil to determine the required dose to effectively increase MCD. Shield-1 induced effective transgene stabilization at 20 mg/kg and in a dose-dependent manner with the highest degree of stabilization at the 60 mg/kg dose (Figure  [1](#F1){ref-type="fig"}B) \[[@B40]\]. However, since our goal was to determine the effect of lipid metabolism on insulin sensitivity, we chose a vehicle other than corn oil to prevent confounding effects of the lipid. Others have reported *in vivo* delivery of Shield-1 in PEG/Tween/NNMDA \[[@B42]\]. Injection of 60 mg/kg Shield-1 with a PEG/Tween/NNMDA vehicle most effectively stabilized the MCD transgene (Figure  [1](#F1){ref-type="fig"}C). Therefore we chose 60 mg/kg Shield-1 in a PEG/Tween/NNMDA vehicle to alter MCD in skeletal muscle in mice.

An acute induction of MCD in skeletal muscle did not alter body weight or glucose sensitivity
---------------------------------------------------------------------------------------------

To assess whether an acute increase in fatty acid oxidation is associated with improvements in body weight and insulin sensitivity in a model of diet induced obesity, we made Tg-fMCD^Skel^ and littermate controls obese and insulin resistant with 15 weeks of high fat diet (HFD) (60% kcal from fat) feeding. An additional group of Tg-fMCD^Skel^ and littermate controls were fed a low fat diet (LFD) (10% kcal from fat) for 15 weeks (Figure  [2](#F2){ref-type="fig"}A). Tg-fMCD^Skel^ and control mice on the high fat diet rapidly gained weight, and there was no difference between genotypes (Figure  [2](#F2){ref-type="fig"}B). Mice on the LFD remained lean (Figure  [2](#F2){ref-type="fig"}B). Glucose sensitivity was examined by performing glucose and insulin tolerance tests. High fat diet-induced glucose intolerance was clearly evident in both genotypes (Figure  [2](#F2){ref-type="fig"}C-E). Tg-fMCD^Skel^ and control mice began with elevated fasting blood glucose levels in the insulin tolerance test and failed to clear blood glucose as efficiently as their lean counterparts on the LFD (Figure  [2](#F2){ref-type="fig"}F). Thus, as expected, Tg-fMCD^Skel^ mice in the absence of the inducing ligand displayed no protection from obesity or insulin resistance.

![**The development of diet-induced obesity and insulin resistance in Tg-fMCD**^**skel**^**mice. (A)** Experimental timeline of control and Tg-fMCD^skel^ mice placed on low fat diet (LFD) or high fat diet (HFD) followed by treatment of Shield-1 to induce MCD within the skeletal muscle. **(B)** Mice were weighed weekly to monitor body weight gain. **(C)** Confirmation of glucose intolerance by glucose tolerance test (GTT). **(D)** Area under the curve for GTT and **(E)** insulin at 15 min after glucose challenge in control and Tg-fMCD^skel^ mice. **(F)** Insulin tolerance test (ITT) confirms insulin resistance in mice fed the high fat diet. (n = 5-8) Data are expressed as means +/- SEM.](1471-2091-15-20-2){#F2}

To gain insight into the role of MCD in regulating metabolic dysfunction in the skeletal muscle, we treated Tg-fMCD^Skel^ and control HFD-induced obese and insulin resistant mice with Shield-1 (60 mg/kg) or vehicle every 48 hours for 2 weeks. This dose of shield increased gastrocnemius MCD activity greater than 5-fold (Figure  [3](#F3){ref-type="fig"}). Despite this large increase in skeletal muscle MCD activity, Shield-1 treatment did not alter body weight in Tg-fMCD^Skel^ or control HFD mice (Figure  [4](#F4){ref-type="fig"}A). Moreover, MCD induction by Shield-1 did not alter glucose sensitivity of these mice (Figure  [4](#F4){ref-type="fig"}B). Insulin measurements from Tg-fMCD^Skel^ HFD Shield-1 treated mice taken during the glucose tolerance test, show no difference in insulin sensitivity compared to control HFD Shield-1 controls; both groups of mice remained insulin resistant compared to lean controls. These data suggest that acute induction of MCD in the skeletal muscle is not sufficient to alter adiposity or insulin sensitivity.

![**Chemical-genetic induction of MCD activity in skeletal muscle.** Malonyl-CoA decarboxylase activity in Tg-fMCD^skel^ and control mice fed low fat and high fat diets treated with Shield-1 (60 mg/kg) or vehicle. (n = 3-4) Data are expressed as means +/- SEM. \*p \< 0.001 by 2-way ANOVA.](1471-2091-15-20-3){#F3}

![**Acute induction of MCD does not reverse diet induced obesity or glucose intolerance**. Tg-fMCD^skel^ and control mice on HFD and LFD received 8 doses of Shield-1 (60 mg/kg) or vehicle control over two weeks. **(A)** Body weights were measured before and after Shield-1 treatment. **(B)** Mice were subjected to a GTT to determine glucose tolerance. (n = 3-10) Data are expressed as means +/- SEM.](1471-2091-15-20-4){#F4}

Acute induction of MCD in skeletal muscle repressed insulin signaling
---------------------------------------------------------------------

To address the specificity of the MCD transgene for recombination and induction, we collected the liver, pancreas and heart which highly express the non-recombined transgene \[[@B40]\]. None of these tissues expressed mCherry (a marker for recombination) or expressed the Tg-fMCD (Shield-1 stabilized MCD) transgene (Figure  [5](#F5){ref-type="fig"}).

![**MCD transgene expression and Shield-1 stabilization is specific to skeletal muscle.** Western blot of **(A)** liver **(B)** pancreas and **(C)** heart tissue extracted from Tg-fMCD^skel^ and control mice on HFD and LFD treated with Shield-1 (5 doses at 60 mg/kg) or vehicle. Samples were blotted for FKBP12 (for transgene stabilization), MCD (endogenous expression), mCherry (transgene expression), and alpha Tubulin (loading control). Positive controls for mCherry and FKBP are derived from skeletal muscle of Tg-fMCD^skel^ mice treated with vehicle or Shield-1.](1471-2091-15-20-5){#F5}

To address possible tissue-specific insulin sensitivity in the skeletal muscle, we performed an *in vivo* insulin stimulation followed by tissue collection. HFD fed Tg-fMCD^Skel^ and control mice received an acute treatment of Shield-1 at 60 mg/kg every 24 hours for 5 days. Six hour fasted mice were injected with insulin 24 hours after the last dose of Shield-1 and gastrocnemius muscle was harvested 10 minutes after the insulin injection. As expected insulin stimulated phosphorylation of AKT Ser^473^ was decreased in Tg-fMCD^Skel^ HFD and control HFD mice compared to lean LFD controls (Figure  [6](#F6){ref-type="fig"}A). Tg-fMCD^Skel^ HFD Shield-1 mice, compared to control HFD Shield-1 controls, showed a further 2-fold suppression in insulin stimulated phosphorylated AKT Ser^473^ relative to total AKT in the skeletal muscle (Figure  [6](#F6){ref-type="fig"}A). Additionally, IRS-1 Ser^302^ phosphorylation was lower in Tg-fMCD^Skel^ HFD gastrocnemius compared to all groups (Figure  [6](#F6){ref-type="fig"}B). Although, GSK3β Ser^9^ phosphorylation was not different between groups (Figure  [6](#F6){ref-type="fig"}C), glycogen synthase Ser^641^ phosphorylation was enhanced in Tg-fMCD^Skel^ HFD gastrocnemius (Figure  [6](#F6){ref-type="fig"}D). Taken together these data suggest that induction of MCD in skeletal muscle exacerbates HFD-induced insulin resistance evidenced by decreased insulin signaling.

![**MCD induction exacerbates defects in diet-induced insulin signaling.** Western blot of gastrocnemius muscle isolated from Tg-fMCD^skel^ and control mice on LFD or HFD given Shield-1 (60 mg/kg) or vehicle for 5 days. Mice were fasted for 6 hours before a 10 min insulin stimulation. **(A)** AKT Ser 473 phosphorylation, normalized to total protein and quantified. **(B)** IRS-1 Ser 302 phosphorylation, normalized to total IRS-1 and quantified. **(C)** GSK3β Ser 9 phosphorylation, normalized to total GSK3β and quantified. **(D)** Glycogen Synthase (GS) Ser 641 phosphorylation, normalized to total Glycogen Synthase and quantified. Data are expressed as means +/- SEM. \*p \< 0.05 by one-way ANOVA.](1471-2091-15-20-6){#F6}

Induction of MCD suppresses genes of fatty acid oxidation
---------------------------------------------------------

Previously, we showed that an acute induction of MCD leads to an increase in fatty acid oxidation *in vivo*\[[@B40]\]. Because malonyl-CoA and MCD are major regulators of skeletal muscle fatty acid oxidation, we examined the effect of inducing MCD on genes in the fatty acid oxidation pathway in obese and insulin resistant mice. Surprisingly, Tg-fMCD^Skel^ HFD Shield-1 treated mice, compared to control HFD Shield-1 treated counterparts, had approximately a 2-fold reduced protein abundance of CPT1B and oxidative phosphorylation complex proteins (Figure  [7](#F7){ref-type="fig"}A). Additionally, we saw Medium Chain Acyl-CoA Dehydrogenase (MCAD) increase in high fat fed mice without an effect of MCD induction (Figure  [7](#F7){ref-type="fig"}B) while Hydroxyacyl-CoA Dehydrogenase alpha subunit (HADHA) did not change between groups (Figure  [7](#F7){ref-type="fig"}C). Due to reduced fatty acid oxidation protein expression, we questioned the possible activation of the energy sensor, AMPK. AMPK phosphorylation at Thr172, the major activating phosphorylation site was not changed by MCD induction (Figure  [7](#F7){ref-type="fig"}D). These data suggest that alterations in AMPK do not play a role in mediating the decrease in insulin sensitivity observed in Tg-fMCD^Skel^ mice.

![**MCD induction suppresses the fatty acid oxidative pathway.** Western blot of gastrocnemius muscle for isolated from Tg-fMCD^skel^ and control mice on LFD or HFD given Shield-1 (60 mg/kg) or vehicle for 5 days. **(A)** CPT1B and OXPHOS complexes (as indicated) were normalized to alpha Tubulin and quantified. Samples were blotted with FKBP12 (for transgene stabilization), mCherry (transgene expression) and alpha Tubulin (loading control). **(B)** MCAD and **(C)** HADHA were normalized to alpha Tubulin and quantified **(D)** AMPK Thr 172 phophorylation was determined, normalized for total AMPK and quantified. Data are expressed as means +/- SEM. \*p \< 0.05 by one-way ANOVA.](1471-2091-15-20-7){#F7}

Because we observed a decrease in CPT1B and components of oxidative phosphorylation, we determined if the decrease was due to regulation at the transcriptional level. Gene expression analysis of gastrocnemius muscle from Tg-fMCD^Skel^ HFD Shield-1 treated mice demonstrated a decrease in Cpt1b mRNA upon MCD induction (Figure  [8](#F8){ref-type="fig"}). The transcriptional regulatory genes Pparα and Pgc1α were unchanged after MCD induction as well as the canonical Pparα target Acot1 (Figure  [8](#F8){ref-type="fig"}). Owning to a possible compensation by carbohydrate oxidation, Pyruvate Dehydrogenase Kinase 4 (Pdk4) was transcriptionally suppressed (Figure  [8](#F8){ref-type="fig"}). These data demonstrate that an acute change in the regulation of skeletal muscle lipid oxidation by MCD in a model of obesity induces a concomitant reduction in the protein and mRNA abundance in genes of fatty acid oxidation.

![**Fatty acid oxidation genes are suppressed upon induction of MCD.** qRT-PCR analysis of Cpt1b, Mcad, Acot1, Pgc1α, Pparα and Pdk4 in gastrocnemius muscle from Tg-fMCD^skel^ and control mice on LFD or HFD given Shield-1 (60 mg/kg) or vehicle for 5 days. Data are expressed as means +/- SEM. \*p \< 0.05 by 2-way ANOVA.](1471-2091-15-20-8){#F8}

Discussion
==========

The role of skeletal muscle fatty oxidation in obesity and glucose intolerance is not clear. A growing number of studies have shown a detrimental effect of skeletal muscle mitochondrial fatty acid oxidation in diet induced insulin resistance and obesity \[[@B5]\]. We have increased MCD to increase the potential for fatty acid oxidation in skeletal muscle of obese mice. Here, we demonstrate that 1) induction of MCD did not lead to changes in body weight in HFD induced obese mice, 2) an acute induction of MCD augmented defects in skeletal muscle insulin signaling in HFD induced obese mice, 3) MCD induction resulted in a suppression of oxidative genes within skeletal muscle. The induction of MCD in the skeletal muscle exacerbated the diabetic phenotype by negatively affecting insulin signaling. These data provide insight into the pathophysiology of skeletal muscle insulin resistance and shows that inducing MCD in already pathogenic mice to facilitate increased fatty acid oxidation does not reverse obesity or glucose intolerance.

The role of skeletal muscle mitochondria in the promotion or protection from metabolic dysfunction is not well understood. Based on the strong correlation between increased lipid consumption and insulin resistance, some have suggested that the accumulation of cytoplasmic lipid intermediates that are often seen in diabetic patients and animal models directly impairs insulin signaling \[[@B19],[@B51]\]. Based on this, and the observation that a sedentary lifestyle promotes metabolic dysfunction, it has been suggested that the stimulation of fatty acid oxidation could lower the concentration of lipotoxic intermediates to improve insulin sensitivity by removing the lipid substrates. In support of this, individuals with type 2 diabetes and even pre-diabetes have decreased mitochondrial function \[[@B13],[@B18],[@B52],[@B53]\]. However, several mouse models with increased lipid oxidation in skeletal muscle do not have improved insulin sensitivity \[[@B25]\]. Inversely, metformin, which is widely used to treat diabetic patients, has been proposed to work as a mild electron transport inhibitor \[[@B54]-[@B56]\]. Also, mice with suppressed function of complex I of the electron transport chain in skeletal muscle are protected from diet induced glucose intolerance \[[@B57]\]. In support of these findings, we were unable to observe improvements in body weight or insulin sensitivity by increasing fatty acid oxidative potential with the over-expression of MCD in our model of high fat diet induced insulin resistance.

Obesity induced insulin resistance is associated with alterations in fatty oxidation genes and mitochondrial dysfunction \[[@B58],[@B59]\]. Human studies support the observation of decreased transcriptional control of fatty acid oxidative genes in the skeletal muscle of obese, highly insulin resistant people. Specifically, individuals in the most insulin resistant and insulin sensitive groups had lowered expression of Pgc1α, Pparα, and Cpt1b \[[@B60]\]. A second study described decreased mRNA content in Pdk4, Pgc1α, and Pparα in obese individuals \[[@B61]\]. In contrast, decreasing fatty acid oxidation by the small molecule inhibition of CPT1, improved insulin sensitivity and increased pyruvate dehydrogenase activity to promote glucose oxidation, and AKT phosphorylation in mice \[[@B62]\]. These studies suggest the skeletal muscle employs different mechanisms to adapt to varying degrees of insulin resistance. The skeletal muscle may use alternate mechanisms to regulate macronutrient substrate switching to increase glucose oxidation in a prolonged state of over nutrition. \[[@B33],[@B63]\].

Skeletal muscle MCD regulates the concentration of malonyl-CoA, the precursor for fatty acid synthesis and elongation. Decreasing the concentration of malonyl-CoA, dysinhibits CPT1, the rate-setting enzyme in mitochondrial fatty acid oxidation. Here we showed that the induction of MCD and thereby increased fatty acid oxidation potential in skeletal muscle in the absence of increased ATP utilization or uncoupling may be a contributing factor in diabetes. That is, unbalancing the flux of macronutrient metabolism from mitochondrial capacity may be an underlying cause of metabolic dysfunction. Interestingly, acute MCD expression in the skeletal muscle down-regulated Cpt1b and other genes in the lipid oxidation pathway at the transcriptional and protein level. In support of this data, MCD knockout mouse hearts or canine hearts subjected to pharmacologic inhibition of fatty acid oxidation, showed the inverse transcriptional alterations \[[@B64],[@B65]\]. These fatty acid oxidation genes are known targets of Pparα transcriptional activation, suggesting a novel mechanism linking intermediary metabolism to Pparα transcriptional regulation. Pparα has been shown to play an important role in the transcriptional regulation of lipid and glucose metabolism, particularly in skeletal muscle fatty acid oxidation \[[@B66]\]. Studies have suggested a wide variety of lipids that function as endogenous Ppar activators \[[@B67],[@B68]\]. Metabolites likely play larger roles in regulating genes and pathways than has been appreciated. We suggest a possible mechanism where increasing MCD results in increased fatty acid intermediates to generate metabolic signals that affect Pparα mediated transcriptional control.

Conclusions
===========

Induction of MCD in pathogenic obese and glucose intolerant skeletal muscle does not improve obesity or insulin resistance. Induction of MCD leads to decreased fatty acid oxidation gene expression, and impaired skeletal muscle insulin signaling. These results suggest that increasing mitochondrial fatty acid oxidative flux in the absence of energy demand contributes to lipid induced insulin resistance.
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